CGEN - Compugen logo

Compugen

CGEN

Compugen Ltd. develops immunotherapy treatments for cancer, focusing on compounds for solid tumors. Its pipeline includes various antibody candidates in clinical trials, targeting immune resistance mechanisms, and collaborating with major pharmaceutical companies.

βš•οΈ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 20 years ago β†’$822today

Score Overview

1 Year
Score
Net Growth-0.43%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth1.70%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score7.0
Net Growth207.05%
Net Trend60%
Net Income Consistencyβ€”
Rev Growth12x
Rev Trend80%
Revenue Consistencyβ€”
10 Years
Score
Net Growth211.70%
Net Trend50%
Net Income Consistency
Rev Growth103x
Rev Trend70%
Revenue Consistency
20 Years
Score4.2
Net Growth370.28%
Net Trend40%
Net Income Consistency
Rev Growth344x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth362.54%
Net Trend42%
Net Income Consistency
Rev Growth10x
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Compugen has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. CGEN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 2.35β€”
1 Year2025-09-29
$ 1.4463.19%
5 Years2021-09-29
$ 5.92-60.30%
10 Years2016-09-29
$ 6.35-62.99%
20 Years2006-09-29
$ 2.86-17.84%
All Time2000-08-11
$ 11.13-78.88%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 74M$ 35M$ 125M
2025$ 72M$ 35M$ 145M
2024$ 27M-$ 14M$ 103M
2023$ 33M-$ 18M$ 50M
2022$ 7M-$ 33M$ 83M
2021$ 6M-$ 32M$ 117M
2020$ 2M-$ 27M$ 123M
2019$ 0.00-$ 27M$ 43M
2018$ 17M-$ 22M$ 45M
2017$ 0.00-$ 37M$ 30M
2016$ 712K-$ 31M$ 61M
2015$ 9M-$ 20M$ 81M
2014$ 12M-$ 11M$ 73M
2013$ 3M-$ 14M$ 51M
2012$ 242K-$ 13M$ 24M
2011-$ 424K-$ 12M$ 22M
2010$ 1M-$ 7M$ 21M
2009$ 250K-$ 3M$ 15M
2008$ 338K-$ 12M$ 11M
2007$ 180K-$ 12M$ 15M
2006$ 215K-$ 13M$ 25M
2005$ 646K-$ 13M$ 30M
2004$ 4M-$ 13M$ 20M
2003$ 8M-$ 11M$ 16M
2002$ 11M-$ 12M$ 18M
2001$ 11M-$ 15M$ 17M
IPO2000$ 6M-$ 13M$ 80M
CGEN - Compugen logo

Compugen fundamental performance

Between 2020 and 2025, revenue grew from $ 2M to $ 72M and net income went from -$ 27M to $ 35M. Revenue increased in 4 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 9M to $ 72M and net income went from -$ 20M to $ 35M. Revenue increased in 7 of those 10 years; net income in 5.

Compugen currently holds a 20-year HDB Score of 4.2 out of 10. How the HDB Score is calculated.

Membership

Explore CGEN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies